Activating CD40 is “a key to initiating a T-cell response to tumors,” says Dr. Robert Vonderheide, MD, director of U Penn’s Abramson Cancer Center.
Original Article: CD40-Activating Monoclonal Antibodies Boost Response to Immunotherapy